Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TransPharma Medical has reported positive results from the Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.
Subscribe to our email newsletter
ViaDor-GLP1 application involves the use of TransPharma’s ViaDor drug delivery system featuring a handheld electronic device, which creates microscopic passageways through the outer layer of the skin for transdermal drug delivery from a patch.
The single-dose, four-way cross over study Phase 1b study was designed to evaluate the pharmacokinetic (PK) profile, safety and tolerability of ViaDor-GLP1 agonist in diabetic patients by using TransPharma’s extended release film patch.
The study involved 14 patients with type II diabetes, and compared once-daily application of three patch formulations versus twice daily subcutaneous injection of Exenatide (Byetta).
The study results demonstrated that ViaDor-GLP1 agonist was safe and well-tolerated with a preferable extended PK profile compared to Byetta.
Transdermal applications of ViaDor-GLP1 agonist lead to therapeutic blood levels for approximately 20 hours compared to 6 hours post injection of Exenatide.
The post postprandial glucose levels were consistent with ViaDor-GLP1 extended PK profiles.